Enveric -CBD Combination Therapies
Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the same or greater therapeutic effect with a lower dose of the chemotherapeutic agent, potentially minimizing the severity of side effects.
Enveric’s CBD molecules target radiodermatitis, glioblastoma multiforme (GBM) and chemotherapy-induced neuropathy. Phase 1 clinical trials are scheduled to begin in 2022 to test if CBD lowers the required dose of chemotherapy in GBM patients while maintaining efficacy, resulting in fewer debilitating side effects and a higher quality of life.